9-methyl-β-carboline has restorative effects in an animal model of Parkinson's disease

Pharmacological Reports

Volumn 62, Issue 1, 2010, Pages 35-53

  Wernicke, Catrin ^a   Hellmann, Julian ^a   Zieba, Barbara ^b   Kuter, Katarzyna ^c   Ossowska, Krystyna ^c   Frenzel, Monika ^a   Dencher, Norbert A ^a   Rommelspacher, Hans ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

^c DARMSTADT UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Dopamine; Neuronal regeneration; Neurotrophins; Parkinson's disease; Rat; Respiratory chain

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 9 METHYL BETA CARBOLINE DERIVATIVE; BETA CARBOLINE DERIVATIVE; BRAIN DERIVED NEUROTROPHIC FACTOR; CEREBELLIN 1 PRECURSOR PROTEIN; CILIARY NEUROTROPHIC FACTOR RECEPTOR; DOPAMINE; PROTEIN PRECURSOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CORPUS STRIATUM; DNA FINGERPRINTING; ENZYME ACTIVITY; GENE EXPRESSION; IMMUNOCOMPETENT CELL; IN VITRO STUDY; LATERAL BRAIN VENTRICLE; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROARRAY ANALYSIS; MITOCHONDRION; NONHUMAN; PARKINSON DISEASE; QUANTITATIVE STUDY; RAT; RESPIRATORY CHAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHAM PROCEDURE; SUBSTANTIA NIGRA; TRANSCRIPTION INITIATION; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

EID: 77950828019     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70241-3     Document Type: Article

References (90)

1. Bartfai T, Lu X, Badie-Mahdavi H, Barr AM, Mazarati A, Hua XY, Yaksh T et al.: Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. Proc Natl Acad Sci USA, 2004, 101, 10470-10475.
2. Batchelor PE, Liberatore GT, Porritt MJ, Donnan GA, Howells D W: Inhibition of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor expression reduces dopaminergic sprouting in the injured striatum. Eur J Neurosci, 2000, 12, 3462-3468.
3. Berger K, Przedborski S, Cadet JL: Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats. Brain Res Bull, 1991,26,301-307.
4. Bjorklund A, Rosenblad C, Winkler C, Kirik D: Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis, 1997, 4, 186-200.
5. Blander G, Guarente L: The Sir2 family of protein deacetylases. Annu Rev Biochem, 2004, 73, 417-435.
6. Bosin TR, Faull K F: Indole derivatization procedures for electron capture negative chemical ionization mass spectrometry: identification of 1-methyl-1,2,3,4-tetrahydro-beta-carboline in rat brain and lung. Biomed Environ Mass Spectrom, 1989, 18, 247-252.
7. Brewer GJ, Jones TT, Wallimann T, Schlattner U: Higher respiratory rates and improved creatine stimulation in brain mitochondria isolated with anti-oxidants. Mitochondrion, 2004, 4, 49-57.
8. Chen YH, Harvey BK, Hoffman AF, Wang Y, Chiang YH, Lupica C R: MPTP-induced deficits in striatal synaptic plasticity are prevented by glial cell line-derived neurotrophic factor expressed via an adeno-associated viral vector. FASEB J, 2008, 22, 261-275.
9. + as enviromental neurotoxins, In: Neurotoxic factors in Parkinson's disease and related disorders. Eds. Storch A, Collins MA, Kluwer Academic, Plenum Press, New York, 2000, 115-130.
10. Collins MA, Neafsey EJ: -carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): en-dogenous factors underlying idiopathic parkinsonism? Neurosci Lett, 1985, 55, 179-184.
11. Collins MA, Neafsey EJ, Matsubara K, Cobuzzi RJ Jr, Rollema H: Indole-N-methylated -carbolinium ions as potential brain-bioactivated neurotoxins. Brain Res, 1992,570,154-160.
12. Cui Q, Harvey AR: CNTF promotes the regrowth of retinal ganglion cell axons into murine peripheral nerve grafts. Neuroreport, 2000, 11, 3999-4002.
13. Dencher NA, Frenzel M, Reifschneider NH, Sugawa M, Krause F: Proteome alterations in rat mitochondria caused by aging. Ann NY Acad Sci, 2007, 1100, 291-298.
14. Douglas R, Kellaway L, Mintz M, van Wageningen G: The crossed nigrostriatal projection decussates in the ventral tegmental decussation. Brain Res, 1987, 418, 111-121.
15. Elliott-Hunt CR, Pope RJ, Vanderplank P, Wynick D: Activation of the galanin receptor 2 (GalR2) protects the hippocampus from neuronal damage. J Neurochem, 2007,100,780-789.
16. Feige JN, Auwerx J: Transcriptional coregulators in the control of energy homeostasis. Trends Cell Biol, 2007,17,292-301.
17. Fekkes D, Bode WT: Occurrence and partition of the beta-carboline norharman in rat organs. Life Sci, 1993, 52,2045-2054.
18. Fornai F, Schluter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, Lazzeri G et al.: Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and -synuclein. Proc Natl Acad Sci USA, 2005, 102, 3413-3418.
19. Gearhart DA, Neafsey EJ, Collins MA: Phenylethanolamine N-methyltransferase has β-carboline 2N-methyl-transferase activity: hypothetical relevance to Parkinrffson's disease. Neurochem Int, 2002, 40, 611-620.
20. Grandier-Vazeille X, Guerin M: Separation by blue native and colorless native polyacrylamide gel electrophoresis of the oxidative phosphorylation complexes of yeast mitochondria solubilized by different detergents: specific staining of the different complexes. Anal Biochem, 1996, 242, 248-254.
21. Gundersen HJ, Jensen EB: The efficiency of systematic sampling in stereology and its prediction. J Microsc, 1987,147,229-263.
22. Hamann J, Wernicke C, Lehmann J, Reichmann H, Rommelspacher H, Gille G: 9-Methyl-β -carboline up-regulates the appearance of differentiated dopaminergic neurones in primary mesencephalic culture. Neurochem Int, 2008, 52, 688-700.
23. Hartnick CJ, Staecker H, Malgrange B, Lefebvre PP, Liu W, Moonen G, Van de Water TR: Neurotrophic effects of BDNF and CNTF, alone and in combination, on postnatal day 5 rat acoustic ganglion neurons. J Neurobiol, 1996, 30, 246-254.
24. Hermann S: Quantification of oxidative phosphorylation enzymes after blue native electrophoresis and two-dimensional resolution: Normal complex I protein amounts in Parkinson's disease conflict with reduced catalytic activities. Electrophoresis, 1995, 16, 763-770.
25. Herraiz T, Chaparro C: Human monoamine oxidase is inhibited by tobacco smoke: β-carboline alkaloids act as potent and reversible inhibitors. Biochem Biophys Res Commun, 2005, 326, 378-386.
26. Hirai H, Pang Z, Bao D, Miyazaki T, Li L, Miura E, Parris J et al.: Cbln1 is essential for synaptic integrity and plasticity in the cerebellum. Nat Neurosci, 2005, 8, 1534-1541.
27. Hobson SA, Bacon A, Elliot-Hunt CR, Holmes FE, Kerr NC, Pope R, Vanderplank P et al.: Galanin - 25 years with a multitalented neuropeptide: Galanin acts as a trophic factor to the central and peripheral nervous systems. Cell Mol Life Sci, 2008, 65, 1806-1812.
28. Honecker H, Rommelspacher H: Tetrahydronorharmane (tetrahydro-beta-carboline), a physiologically occurring compound of indole metabolism. Naunyn Schmiedebergs Arch Pharmacol, 1978, 305, 135-141.
29. Horton AR, Barlett PF, Pennica D, Davies AM: Cytokines promote the survival of mouse cranial sensory neurones at different developmental stages. Eur J Neurosci, 1998,10,673-679.
30. Keeney PM, Xie J, Capaldi RA, Bennett JP Jr.: Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci, 2006, 26, 5256-5264.
31. Kotzbauer PT, Holtzman DM: Expectations and challenges in the therapeutic use of neurotrophic factors. Ann Neurol, 2006, 59, 444-447.
32. Krause F, Seelert H: Detection and analysis of protein-protein interactions of organellar and prokaryotic proteomes by blue native and colorless native gel electrophoresis. Curr Protoc Protein Sci, 2008, Chapter 14, Unit 14 11
33. Kuhn W, Muller T, Grosse H, Rommelspacher H: Elevated levels of harman and norharman in cerebrospinal fluid of parkinsonian patients. J Neural Transm, 1996, 103,1435-1440.
34. Kuonen DR, Roberts PJ, Cottingham IR: Purification and analysis of mitochondrial membrane proteins on nondenaturing gradient polyacrylamide gels. Anal Biochem, 1986, 153, 221-226.
35. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ et al.: Randomized controlled trial of intrapu-tamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol, 2006, 59, 459-466.
36. Leviel V, Cheramy A, Glowinski J: Role of the dendritic release of dopamine in the reciprocal control of the two nigro-striatal dopaminergic pathways. Nature, 1979, 280, 236-239.
37. Lindholm P, Voutilainen MH, Lauren J, Peranen J, Leppanen VM, Andressoo JO, Lindahl M et al.: Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature, 2007, 448, 73-77.
38. -ΔΔCT Method. Methods, 2001, 25, 402-408.
39. Lorenc-Koci E, Rommelspacher H, Schulze G, Wernicke C, Kuter K, Smiałowska M, Wierońska J, et al.: Parkinson's disease-like syndrome in rats induced by 2,9-dimethyl- β -carbolinium ion, a -carboline occurring in the human brain. Behav Pharmacol, 2006, 17, 463-473.
40. Mahoney SA, Hosking R, Farrant S, Holmes FE, Jacoby AS, Shine J, Iismaa T P et al.: The second galanin receptor GalR2 plays a key role in neurite outgrowth from adult sensory neurons. J Neurosci, 2003, 23, 416-421.
41. Marshall J F: Somatosensory inattention after dopamine-depleting intracerebral 6-OHDA injections: spontaneous recovery and pharmacological control. Brain Res, 1979, 177, 311-324.
42. Matsubara K: Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease (Japanese). Nihon Hoigaku Zasshi, 1998, 52, 301-305.
43. Matsubara K, Collins MA, Akane A, Ikebuchi J, Neafsey EJ, Kagawa M, Shiono H: Potential bioactivated neurotoxicants, N-methylated beta-carbolinium ions, are present in human brain. Brain Res, 1993, 610, 90-96.
44. + and -carbolinium in the striatum of conscious rats. Eur J Pharmacol, 1996, 315, 145-151.
45. + analogs, in the lumbar cerebrospinal fluid of patients with Parkinson's disease. Neurology, 1995, 45, 2240-2245.
46. 3H]harman binding experiments. II: Regional and subcellular distribution of specific [H]harman binding and monoamine oxidase subtypes A and B activity in marmoset and rat. J Neurochem, 1991, 56, 500-508.
47. 3H]harman binding experiments. I: A reversible and selective radioligand for monoamine oxidase subtype A in the CNS of the rat. J Neurochem, 1991, 56, 490-499.
48. +. Neuroreport, 2004, 15, 1039-1044.
49. Moore R Y: Organization of midbrain dopamine systems and the pathophysiology of Parkinson's disease. Parkin- sonism Relat Disord, 2003, 9 S65-71.
50. Morgan S, Huston J P: The interhemispheric projection from the substantia nigra to the caudate-putamen as depicted by the anterograde transport of [H]leucine. Behav Brain Res, 1990, 38, 155-162.
51. Muthane U, Ramsay KA, Jiang H, Jackson-Lewis V, Donaldson D, Fernando S, Ferreira M et al.: Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice. Exp Neurol, 1994, 126, 195-204.
52. Neff D, Dencher N A: Purification of multisubunit membrane protein complexes: isolation of chloroplast FoF1-ATP synthase, CFo and CF1 by blue native electrophoresis. Biochem Biophys Res Commun, 1999, 259, 569-575.
53. Nicklas WJ, Vyas I, Heikkila R E: Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci, 1985,36,2503-2508.
54. Nishimune H, Vasseur S, Wiese S, Birling MC, Holtmann B, Sendtner M, Iovanna J L et al.: Reg-2 is a moto- neuron neurotrophic factor and a signalling intermediate in the CNTF survival pathway. Nat Cell Biol, 2000, 2, 906-914.
55. Nosheny RL, Ahmed F, Yakovlev A, Meyer EM, Ren K, Tessarollo L, Mocchetti I: Brain-derived neurotrophic factor prevents the nigrostriatal degeneration induced by human immunodeficiency virus-1 glycoprotein 120 in vivo. Eur J Neurosci, 2007, 25, 2275-2284.
56. Ossowska K, Wardas J, Smiałowska M, Kuter K, Lenda T, Wierońska JM, Zieba B, et al.: A slowly developing dysfunction of dopaminergic nigrostriatal neurons induced by long-term paraquat administration in rats: an animal model of preclinical stages of Parkinson's disease? Eur J Neurosci, 2005, 22, 1294-1304.
57. Ossowska K, Smiałowska M, Kuter K, Wierońska J, Zieba B, Wardas J, Nowak P, et al.: Degeneration of do- paminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats: implications for Parkinson's disease. Neuroscience, 2006, 141, 2155-2165.
58. Pallas M, Pizarro JG, Gutierrez-Cuesta J, Crespo-Biel N, Alvira D, Tajes M, Yeste-Velasco M et al.: Modulation of SIRT1 expression in different neurodegenerative models and human pathologies. Neuroscience, 2008, 154,1388-1397.
59. Paxinos C, Watson C: The rat brain in sterotaxic coordinates. London, Academic Press, 1986.
60. Paxinos G, Watson C, Pennisi M, Topple A: Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight. J Neurosci Methods, 1985, 13, 139-143.
61. Petrova P, Raibekas A, Pevsner J, Vigo N, Anafi M, Moore MK, Peaire A E et al.: MANF: a new mesen- cephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J Mol Neurosci, 2003,20,173-188.
62. Pimpinella G, Palmery M: Interaction of beta-carbolines with central dopaminergic transmission in mice: structure-activity relationships. Neurosci Lett, 1995, 189, 121-124.
63. Polanski W, Rommelspacher H, Reichmann H, Gille G: 9-methyl- β -carboline exhibits a unique tetrad of effects: stimulation, protection, and regeneration of dopaminer-gic neurons coupled with anti-inflammatory action. Pro-ceedings from the symposium "Neurobiology of Neuro-Psychiatric Diseases", Jerusalem, Israel, 2-5 November 2008. J Neural Transm, 2009, 116, 250, P166.
64. Reifschneider NH, Goto S, Nakamoto H, Takahashi R, Sugawa M, Dencher NA, Krause F: Defining the mitochondrial proteomes from five rat organs in a physiologically significant context using 2D bluenative/SDS-PAGE. J Proteome Res, 2006, 5, 1117-1132.
65. Rommelspacher H, May T, Salewski B: Harman (1-methyl- β -carboline) is a natural inhibitor of monoamine oxidase type A in rats. Eur J Pharmacol, 1994,252,51-59.
66. Sällström Baum S, Hill R, Rommelspacher H: Harman-induced changes of extracellular concentrations of neurotransmitters in the nucleus accumbens of rats. Eur J Pharmacol, 1996, 314, 75-82.
67. Sällström Baum S, Hill R, Rommelspacher H: Norharman-induced changes of extracellular concentrations of dopamine in the nucleus accumbens of rats. Life Sciences, 1995, 56, 1715-1720.
68. Scarpulla RC: Nuclear control of respiratory gene expression in mammalian cells. J Cell Biochem, 2006, 97, 673-683.
69. Schaefer E, Seelert H, Reifschneider NH, Krause F, Dencher NA, Vonck J: Architecture of active mammalian respiratory chain supercomplexes. J Biol Chem, 2006, 281,15370-15375.
70. Schagger H: Quantification of oxidative phosphorylation enzymes after blue native electrophoresis and two- dimensional resolution: normal complex I protein amounts in Parkinson's disease conflict with reduced catalytic activities. Electrophoresis, 1995, 16, 763-770.
71. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD: Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem, 1990, 54, 823-827.
72. Schapira AH, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark J B et al.: Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem, 1990, 55, 2142-2145.
73. Seniuk NA, Tatton WG, Greenwood C E: Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res, 1990, 527, 7-20.
74. Siegel SG, Patton B, English A W: Ciliary neurotrophic factor is required for motoneuron sprouting. Exp Neurol, 2000,166,205-212.
75. Sinclair D A: Toward a unified theory of caloric restriction and longevity regulation. Mech Ageing Dev, 2005, 126,987-1002.
76. Slemmon JR, Danho W, Hempstead JL, Morgan JI: Cerebellin: a quantifiable marker for Purkinje cell maturation. Proc Natl Acad Sci USA, 1985, 82, 7145-7148.
77. Sonsalla PK, Giovanni A, Sieber BA, Donne KD, Manzino L: Characteristics of dopaminergic neurotoxicity produced by MPTP and methamphetamine. Ann NY Acad Sci, 1992, 648, 229-238.
78. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, Handschin C et al.: Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell, 2006, 127, 397-408.
79. Sterio D C: The unbiased estimation of number and sizes of arbitrary particles using the disector. J Microsc, 1984, 134,127-136.
80. Susilo R, Rommelspacher H: Formation of a betacarboline (1,2,3,4-tetrahydro-1-methyl-beta-carboline-1-carboxylic acid) following intracerebroventricular injection of tryptamine and pyruvic acid. Naunyn Schmiedebergs Arch Pharmacol, 1987, 335, 70-76.
81. 123I] β-CIT SPECT. J Neurol 1998,245,14-20.
82. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature, 1991, 349,414-418.
83. Urade Y, Oberdick J, Molinar-Rode R, Morgan JI: Precerebellin is a cerebellum-specific protein with similarity to the globular domain of complement C1q B chain. Proc Natl Acad Sci USA, 1991, 88, 1069-1073.
84. Veereshwarayya V, Kumar P, Rosen KM, Mestril R, Querfurth H W: Differential effects of mitochondrial heat shock protein 60 and related molecular chaperones to prevent intracellular β-amyloid-induced inhibition of complex IV and limit apoptosis. J Biol Chem, 2006, 281, 29468-29478.
85. Wei P, Smeyne RJ, Bao D, Parris J, Morgan J I: Mapping of Cbln1-like immunoreactivity in adult and developing mouse brain and its localization to the endolysosomal compartment of neurons. Eur J Neurosci, 2007, 26, 2962-2978.
86. Weinreb O, Amit T, Bar-Am O, Youdim M B: Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann NY Acad Sci, 2007, 1122, 155-168.
87. Wernicke C, Schott Y, Enzensperger C, Schulze G, Lehmann J, Rommelspacher H: Cytotoxicity of betacarbolines in dopamine transporter expressing cells: structure-activity relationships. Biochem Pharmacol, 2007,74,1065-1077.
88. Yang P, Arnold SA, Habas A, Hetman M, Hagg T: Ciliary neurotrophic factor mediates dopamine D2 receptor-induced CNS neurogenesis in adult mice. J Neurosci, 2008, 28, 2231-2241.
89. +). Exp Neurol, 2006, 200, 172-183.
90. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker E M: Compensations after lesions of central do- paminergic neurons: some clinical and basic implications. Trends Neurosci, 1990, 13, 290-296.